Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, P.R. China.
Clin Otolaryngol. 2021 Jul;46(4):802-808. doi: 10.1111/coa.13738. Epub 2021 Feb 27.
To identify whether chemoradiotherapy improves survival in patients with stage T3-4N0M0 nasopharyngeal carcinoma (NPC).
The data of patients with stage T3-4N0M0 NPC were extracted from the Surveillance, Epidemiology, and End Results database between 2004 and 2016. The patients were divided into radiotherapy and chemoradiotherapy groups. Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan-Meier method and propensity score matching (PSM) analyses.
We examined 496 patients: 88 who received radiotherapy and 408 who received chemoradiotherapy. Before PSM, chemoradiotherapy was associated with a better 5-year OS (52.58% vs. 38.13%; P = .005) and similar CSS (63.62% vs. 59.26%; P = .196) compared to those associated with radiotherapy. However, chemoradiotherapy was not an independent prognostic factor for OS [hazard ratio (HR)=0.95, 95% confidence interval (CI): 0.68-1.32; P = .760] or CSS (HR = 1.02, 95% CI: 0.66-1.56; P = .935). After PSM, similar OS (45.15% vs. 42.78%; P = .626) and CSS (58.22% vs. 60.37%; P = .730) were found between the radiotherapy and chemoradiotherapy groups.
Radiotherapy and chemoradiotherapy are associated with similar OS and CSS in patients with stage T3-4N0M0 NPC.
确定放化疗是否能提高 T3-4N0M0 期鼻咽癌（NPC）患者的生存率。
从 2004 年至 2016 年，从监测、流行病学和结果数据库中提取 T3-4N0M0 期 NPC 患者的数据。将患者分为放疗组和放化疗组。采用 Kaplan-Meier 法和倾向评分匹配（PSM）分析评估总生存期（OS）和癌症特异性生存期（CSS）。
共纳入 496 例患者：88 例接受放疗，408 例接受放化疗。在 PSM 之前，与放疗相比，放化疗患者 5 年 OS（52.58% vs. 38.13%；P=0.005）和 CSS（63.62% vs. 59.26%；P=0.196）均有改善。然而，放化疗并不是 OS（风险比[HR]=0.95，95%置信区间[CI]：0.68-1.32；P=0.760）或 CSS（HR=1.02，95%CI：0.66-1.56；P=0.935）的独立预后因素。PSM 后，放疗组和放化疗组的 OS（45.15% vs. 42.78%；P=0.626）和 CSS（58.22% vs. 60.37%；P=0.730）相似。
放化疗与 T3-4N0M0 期 NPC 患者的 OS 和 CSS 相关。
